Crown Crafts, Inc. (CRWS) Reaches $6.65 Yearly Low, Cyclacel Pharmaceuticals (CYCC) Shorts Increased By 29.61%

July 6, 2017 - By wolcottdaily

The stock of Crown Crafts, Inc. (NASDAQ:CRWS) hit a new 52-week low and has $6.05 target or 9.00% below today’s $6.65 share price. The 7 months bearish chart indicates high risk for the $65.01 million company. The 1-year low was reported on Jul, 6 by Barchart.com. If the $6.05 price target is reached, the company will be worth $5.85M less. The stock decreased 4.32% or $0.3 on July 6, reaching $6.65. About 12,383 shares traded. Crown Crafts, Inc. (NASDAQ:CRWS) has declined 14.68% since July 6, 2016 and is downtrending. It has underperformed by 31.38% the S&P500.

Cyclacel Pharmaceuticals Incorporated (NASDAQ:CYCC) had an increase of 29.61% in short interest. CYCC’s SI was 350,600 shares in July as released by FINRA. Its up 29.61% from 270,500 shares previously. With 42,200 avg volume, 8 days are for Cyclacel Pharmaceuticals Incorporated (NASDAQ:CYCC)’s short sellers to cover CYCC’s short positions. The SI to Cyclacel Pharmaceuticals Incorporated’s float is 13.48%. The stock increased 0.28% or $0.01 on July 6, reaching $3.64. About 105,921 shares traded or 108.16% up from the average. Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) has risen 10.62% since July 6, 2016 and is uptrending. It has underperformed by 6.08% the S&P500.

Crown Crafts, Inc. operates indirectly through its subsidiaries, Crown Crafts Infant Products, Inc. and Hamco, Inc., in the infant and toddler products segment within the consumer products industry. The company has market cap of $65.01 million. The Firm operates though the segment of infant and toddler products. It has a 11.99 P/E ratio. These products consist of infant and toddler bedding, bibs, soft bath products, disposable products and accessories.

Investors sentiment decreased to 0.81 in 2016 Q4. Its down 2.69, from 3.5 in 2016Q3. It dived, as 3 investors sold Crown Crafts, Inc. shares while 13 reduced holdings. 4 funds opened positions while 9 raised stakes. 4.43 million shares or 52.75% less from 9.37 million shares in 2016Q3 were reported. Lsv Asset Management holds 0% of its portfolio in Crown Crafts, Inc. (NASDAQ:CRWS) for 45,122 shares. Zurcher Kantonalbank (Zurich Cantonalbank) holds 0% in Crown Crafts, Inc. (NASDAQ:CRWS) or 9,123 shares. Ny State Common Retirement Fund invested in 0% or 56,604 shares. Cutter Brokerage has 56,800 shares for 0.18% of their portfolio. Brandywine Glob Inv Mgmt stated it has 0% in Crown Crafts, Inc. (NASDAQ:CRWS). Wellington Management Grp Llp reported 0% in Crown Crafts, Inc. (NASDAQ:CRWS). Morgan Stanley, a New York-based fund reported 7,566 shares. Vanguard Group Inc has invested 0% of its portfolio in Crown Crafts, Inc. (NASDAQ:CRWS). New York-based Renaissance Techs Ltd Llc has invested 0% in Crown Crafts, Inc. (NASDAQ:CRWS). Dalton Greiner Hartman Maher & holds 0.01% or 26,070 shares. Blackrock Fund Advisors holds 0% of its portfolio in Crown Crafts, Inc. (NASDAQ:CRWS) for 29,020 shares. The Illinois-based Ariel Investments Ltd Liability Corporation has invested 0.04% in Crown Crafts, Inc. (NASDAQ:CRWS). Manufacturers Life The accumulated 577 shares or 0% of the stock. Northern owns 21,633 shares or 0% of their US portfolio. Raymond James & Assoc holds 0% of its portfolio in Crown Crafts, Inc. (NASDAQ:CRWS) for 42,150 shares.

Cyclacel Pharmaceuticals, Inc. operates in the field of cell cycle biology. The company has market cap of $15.14 million. The Firm has generated various families of anticancer drugs that act on the cell cycle, including nucleoside analogs, cyclin dependent kinase inhibitors, polo-like kinase (PLK) inhibitors and Aurora Kinase/vascular endothelial growth factor receptor (AK/VEGFR) inhibitors. It currently has negative earnings. The Company’s family of anticancer drugs that act on the cell cycle include sapacitabine, seliciclib and CYC065.